ROIV News and Press, Roivant Sciences Ltd. From 02/06/26

2026-02-06 07:07:16 ET More on Roivant Sciences Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Roivant Sciences Ltd. (ROIV) Pr...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ 21.6 P<0.0001) All brepocitinib 45 mg patients achieved a clinically meaningful response, with 10...

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace in pulmonary hypertension associated with interstitial lung disease Topline results on track for second half of calendar year 2026 WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Pu...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other e...

Biogen Inc. (BIIB) is expected to report $1.6 for Q4 2025 Frontier Group Holdings Inc. (ULCC) is expected to report $0.02 for Q4 2025 Johnson Outdoors Inc. (JOUT) is expected to report $-0.45 for Q1 2026 Piper Sandler Companies (PIPR) is expected to report $4.72 for Q4 2025 Ispire...

2026-02-05 10:53:02 ET More on Roivant Sciences Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Roivant Sciences Ltd. (ROIV) Pr...

2026-02-02 14:21:12 ET More on Arbutus Biopharma Arbutus falls as patent dispute with Moderna hits EU snag Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma ...

2026-01-29 03:47:28 ET ... Read the full article on Seeking Alpha For further details see: Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth

DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. To access the Roivant (Nasda...

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, an...